Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation.

Department of Hypertension at the Institute of Cardiology, Warsaw, Poland.
Nature Clinical Practice Endocrinology &#38 Metabolism (Impact Factor: 7.55). 03/2008; 4(2):111-5. DOI: 10.1038/ncpendmet0726
Source: PubMed

ABSTRACT A 46-year-old man presented with headaches, paroxysmal palpitations, anxiety and hypertension. The patient had undergone surgery for a retroperitoneal tumor at the age of 31 years, when histological examination revealed an extra-adrenal pheochromocytoma. The patient's 68-year-old mother had a history of a carotid body tumor, which had been resected when she was 34 years old. She was diagnosed with a meningioma at 54 years of age and a jugular paraganglioma at 68 years of age.
A 24h urine catecholamine assay was performed. CT imaging of the abdomen and (123)I-labeled metaiodobenzylguanidine scintigraphy revealed a right pheochromocytoma and left adrenal incidentaloma. An inherited neoplasia syndrome was suspected and molecular genetic analyses were performed.
Right adrenal pheochromocytoma and left adrenal nonfunctioning incidentaloma, as part of a familial pheochromocytoma-paraganglioma syndrome associated with a germline mutation in SDHC (gene encoding succinate dehydrogenase complex, subunit C, integral membrane protein, 15 kDa).
Predictive testing, with genetic counseling. Management included surgical resection of the existing pheochromocytoma. The patient continues to be monitored with MRI scans of the neck, thorax, abdomen and pelvis every 1-2 years and an annual 24h urine collection for the measurement of metanephrines and catecholamines.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondrial succinate dehydrogenase (SDH) is localized to the inner mitochondrial membrane and is responsible for the redox of succinic acid. SDH is a tetrameric iron-sulfur flavoprotein of the tricarboxylic acid cycle and respiratory chain. The SDH complex, subunit C (SDHC) transcript has deletion-type alternative splicing sites. Generally, alternative splicing produces variant proteins and expression patterns, as products of different genes. In certain cases, specific alternative splicing variants (ASVs) have been associated with human disease. Due to a frameshift mutation causing loss of the heme binding region, the SDHC Δ5 isoform (lacking exon 5) exhibits no SDHC activity. To investigate whether the SDHC splicing variants can function as dominant-negative inhibitors, SDHC ASVs were overexpressed in HCT-15 human colorectal cancer cells. Using real-time reverse transcription-polymerase chain reaction, a dominant-negative effect of the Δ5 isoform on SDHC mRNA was shown. In addition, Δ5 overexpression increased the levels of reactive oxygen species. Furthermore, in the Δ5 isoform-overexpressing cells, SDH activity was reduced. SDHC activation is a significant event during the electron transport chain, and the function of the SDHC Δ5 variant may be significant for the differentiation of tumor cells.
    Oncology letters 01/2015; 9(1):330-334. DOI:10.3892/ol.2014.2699 · 0.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer can be characterized as a state of multifaceted cellular deregulation including control of proliferation and bioenergetics. The latter involves in particular mitochondria, the site of the generation of ATP, essential for the proper cellular function (including proliferation). Mitochondria also contain a variety of proteins that are necessary for the induction/promotion, as well as for the prevention of cell death. Therefore, mitochondria are pivotal in deciding the fate of a cell. In cancer, mitochondria are dysfunctional, which was observed as early as in the 1930s by Otto Warburg. Due to the central role of mitochondria, these organelles, endowed with its own DNA, are a focus of research as possible "culprits" for the malignancy of cancer cells (or at least contributing to this phenotype) and, importantly, as emerging targets for anticancer therapy.
    Progress in molecular biology and translational science 01/2014; 127C:211-227. DOI:10.1016/B978-0-12-394625-6.00008-8 · 3.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Complex II of the respiratory chain (RC) recently emerged as a prominent regulator of cell death. In both cancer cells as well as neurodegenerative diseases, mutations in subunits have been found along with other genetic alterations indirectly affecting this complex. Anticancer compounds were developed that target complex II and cause cell death in a tumour-specific way. Our mechanistic understanding of how complex II is activated for cell death induction has recently been made clearer in recent studies, the results of which are covered in this review. This protein assembly is specifically activated for cell death via the dissociation of its SDHA and SDHB subunits from the membrane-anchoring proteins through pH change or mitochondrial Ca(2+) influx. The SDH activity contained in the SDHA/SDHB subcomplex remains intact and then generates, in an uncontrolled fashion, excessive amounts of reactive oxygen species (ROS) for cell death. Future studies on this mitochondrial complex will further elucidate it as a target for cancer treatments and reveal its role as a nexus for many diverse stimuli in cell death signalling.
    Mitochondrion 06/2014; 19. DOI:10.1016/j.mito.2014.06.001 · 3.52 Impact Factor